This is a significant strategic entry into the TAVR market, a high-growth structural heart segment where BSX currently has no product. The SIEGEL valve's differentiated design (nickel-free, smaller sheath) and early clinical data position it as a potential competitor to Edwards and Medtronic. Watch for STAR trial enrollment updates and FDA milestone announcements as catalysts for the call option exercise. The $3.0 billion option price implies a ~$4.5 billion total enterprise value for the TAVR asset, which is reasonable given the market opportunity.
Price Chart
Executive Summary
Boston Scientific invested $1.5 billion for a 33.75% equity stake in MiRus LLC, a privately-held developer of the SIEGEL TAVR system, and obtained an exclusive option to acquire the TAVR business for an additional $3.0 billion upon achievement of clinical and regulatory milestones. The investment provides BSX with a differentiated, nickel-free balloon-expandable TAVR valve currently in a pivotal trial, though the device remains investigational and not yet approved for commercial sale.
Key Facts
- BSX acquired 33.75% of MiRus for $1.5 billion cash (plus a prior $100 million payment) on May 15, 2026.
- BSX holds an exclusive call option to acquire the TAVR-Structural Heart NewCo for an additional $3.0 billion in cash upon milestone achievement.
- The SIEGEL TAVR valve is the first nickel-free, balloon-expandable TAVR system, delivered through an 8 French sheath (50% smaller than current sheaths).
- MiRus recently initiated the STAR pivotal trial (up to 1,025 patients) for FDA PMA approval.
- The investment is expected to be immaterial to BSX's adjusted EPS in 2026.
- If BSX does not exercise the call option, its equity stake will be forfeited or reduced by ~75%.
Financial Impact
$1.5 billion cash investment for 33.75% stake, with a potential additional $3.0 billion for full ownership of the TAVR business; immaterial to 2026 adjusted EPS.
Risk Factors
- The SIEGEL valve is investigational and not yet approved in any country; pivotal trial failure or regulatory delays could impair the investment.
- If BSX does not exercise the call option, the $1.5 billion equity stake is largely forfeited (~75% reduction), representing a substantial loss.
- Integration risk and competition from established TAVR players (Edwards, Medtronic) could limit commercial uptake even if approved.
- The $3.0 billion option payment plus potential sales-based milestones represent significant future cash outflows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000041 |
| Exhibit: exhibit991-pressrelease_fi.htm | 0000885725-26-000041 |
| Document: 0000885725-26-000041-index-headers.html | 0000885725-26-000041 |
| Document: 0000885725-26-000041-index.html | 0000885725-26-000041 |
| Document: 0000885725-26-000041.txt | 0000885725-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $43.23 (−10.50%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $43.23 (+10.26%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $43.23 (−11.79%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $43.23 (−9.45%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $43.23 (+6.10%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $43.23 (−6.14%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $43.23 (−5.01%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $43.23 (−3.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access